Startups
Categories: BioTechInvestment
Bruce Booth, partner at Atlas Venture, blogs on all facets of early stage biotech.
Website visits
23.6K /mo.
Mentions
109
Mentions in press and media 109
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 1, 2023 | Johnson & Johnson bets heavy on AI-driven drug discovery | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about h... |
| Mar 15, 2023 | Drug developers navigating ‘biology’s century’ need a model. We made one | STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry is “not prepared for the next wave of biotech innovation.” His report ends on a somewhat dismal note: the industry is long on diagnosis (clinica... |
| May 31, 2022 | Biotech Venture Capital’s Uneasy Future–The Fed’s Impact On Innovation | WASHINGTON, DC - Federal Reserve Board Chairman Jerome Powell discusses interest rates set by the ... [+] Fed. (Photo by Samuel Corum/Getty Images) Getty Images |
| Mar 9, 2022 | Altos Labs’ Mega-Startup: Wretched Excess Or The Future Of Biotech…Or Both? | Alta Labs - the biggest biotech startup in history. Photo credit: Getty getty |
| Dec 9, 2021 | Viatris and Biocon mull pooling their biosimilars into a $10B standalone company — report | Those megabillion biobuck deals: Do they work? Are they ever paid? It’s the question looming behind most biotech buyouts and licensing deals, which now almost always come stuffed with developmental, regulatory and sales milestones. Take Roc... |
| Oct 7, 2021 | A new wave of drug startups with big portfolios and precarious valuations has burst onto the scene. Welcome to the era of 'mega biotechs.' | In the past two years, a wave of new drug companies has emerged that meld multiple smaller startups to either create a single new venture or a holding company with many subsidiaries. iStock; Skye Gould/Insider This story is available exclus... |
| Jan 27, 2021 | A New Perspective On How To Fix Pharma’s Broken Business Model | Biopharma has brought miracle cures. With leadership, the industry could do so much more. getty |
| Jan 4, 2021 | The Biotech Paradox Of 2020: A Year In Review | 2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. |
| Nov 20, 2020 | Biotech: The Featherweight Champion Of The Markets | getty |
| Oct 27, 2020 | An evolution in early stage gene therapy funding models | A tsunami of curative gene therapies for rare diseases will get through pivotal trials in the coming year or two. This comes on the back of substantial venture-capital finance which has brought these programs out of gestation in academic la... |
| Oct 22, 2020 | Biden And Trump Drug Pricing Policies Would Decimate Biotech, Drive Innovation To China | President Donald Trump signs an executive order linking drug prices to rates paid in other ... [+] countries. Photographer: Stefani Reynolds/Bloomberg© 2020 Bloomberg Finance LP |
| Oct 15, 2020 | It’s Raining Biotech SPACs! | SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been fueling up their tanks and chasing down their merg... |
| Oct 15, 2020 | Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip | Jim Tananbaum was looking for a specific type of company, one with a genetics-driven platform, when he launched Foresite Capital’s first blank check company. And he’s found it in Gemini Therapeutics. Just two months aft... |
| Oct 2, 2020 | Can Pharma-Biotech Alliances Solve The Innovation Crisis And Save The Industry? | Pharma cannot make enough new medicines to meet the needs of patients. (AP Photo/Elise Amendola)ASSOCIATED PRESS |
| Sep 21, 2020 | Evolution Of The Biotech IPO Markets From Busted To Booming | getty |
| Jul 24, 2020 | Debating Drug Prices In The Shadow Of Coronavirus: Access Vs Innovation. Can Both Sides Win? | Debating drug prices during the COVID-19 Coronavirus pandemic. (Photo by Horacio ... [+] Villalobos#Corbis/Corbis via Getty Images)Corbis via Getty Images |
| Jul 15, 2020 | The Record-Breaking Biotech Funding Tsunami Of 1H2020 | We’re half way through one of the craziest years in recent memory, with a raging viral pandemic, civil unrest and protests, staggering unemployment and economic woes, and invasive murder hornets. And yet, like the indefatigable Energizer bu... |
| Apr 17, 2020 | Value Creation And Destruction: Dispersion Of Performance In Biotech IPOs | The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year. And the queue for companies with active S1’s... |
| Apr 8, 2020 | Weathering the storm: Another biotech braves Covid-19 in upsized IPO | Zentalis isn’t the only biotech to defy expectations as financial markets across the globe roil from the shock of the coronavirus pandemic. Keros Therapeutics has managed to execute an IPO, hitting the top end of its pr... |
| Mar 26, 2020 | Strategic Planning In Biotech During A Pandemic Crisis | Life scientists researching in laboratory. Getty |
| Mar 12, 2020 | Atlas-backed Kymera grabs $102M as its protein degradation technology heads into clinic | When Bruce Booth and Nello Mainolfi started planning a protein degradation company, the field was open and sparse, dotted with a couple of hopeful startups and larger players making exploratory forays. Booth called it a “... |
| Mar 2, 2020 | Something Ventured: Vor Biopharma and 3 other startups got venture funding a year ago. Did it help them do what they said it would? | This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here. Every quarter, the CEO of a public biotech company can expect to spend an hour or tw... |
| Mar 2, 2020 | BioPharma M&A Drives More Efficient Resource Allocation | M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. |
| Aug 15, 2019 | The Creation Of Biotech Startups: Evolution Not Revolution | The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying alternative models of company creation (here,... |
| Apr 1, 2019 | Atlas wraps Arteaus story with $260M royalty sale as Emgality sales inches upward | Six months after Eli Lilly notched a second-runner-up approval for its CGRP migraine drug Emgality, the Atlas-founded biotech that brought it over the proof-of-concept gate five years ago has sold all its royalty interest fo... |
| Jan 17, 2019 | Zafgen has something to cheer as diabetes drug makes the cut in PhII study | After being plagued by a laundry list of setbacks that culminated in the desertion of its obesity drug and the departure of its CEO, Zafgen finally has some good news to report. Data from a cohort of a mid-stage study sug... |
| Jan 15, 2019 | Is JPM Week worth it from a press perspective? | Booth writes from not only an investor perspective — he is a partner at Atlas Venture — but also as a compassionate human being portraying the stark contrast of tailored suits streaming on the streets of San Francisco with the obvious pover... |
| Jan 14, 2019 | Is JPM worth it? As the buzzy conference dies down, debate on its value rumbles on | The exorbitant cost of attending JPMorgan — from hotels and flights to coffee and meeting space — has long been a talking point for biopharma execs gathering in San Francisco every January. But as the industry’s signa... |
| Jun 6, 2018 | Pfizer devotes $150 million to neuroscience in venture capital funding increase | The move comes half a year after the company closed its research and development efforts in neuroscience, cutting more than 300 jobs, primarily in Massachusetts and Connecticut. However, it was reported at the time that it would devote vent... |
| Dec 14, 2017 | Its underlying biology 'too complicated' for further investment, Atlas-seeded Raze signs off | Raze Therapeutics, the Cambridge startup that launched in 2014 with $24 million in support, is calling it quits. The company was looking to advance a new class of cancer therapeutics that target key metabolic pathways, b... |
| Nov 17, 2017 | What's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine | Atlas Venture sounded taps for biotech startup Quartet Medicine this morning — done in by a troubling tox signal that scuttled its plans to develop a new chronic pain med. Bruce Booth Atlas partner Bruce Booth wrote a detai... |
| Nov 15, 2017 | Genentech inks $650M deal with protein degradation pioneer Arvinas | Genentech is doubling down on its commitment to New Haven biotech Arvinas, extending the duo’s partnership and tacking an additional $350 million onto the total deal value. The companies have been working together sinc... |
| Nov 7, 2017 | What happens when you sell your startup? | Jason Rowley Contributor Jason Rowley is a venture capital and technology reporter for Crunchbase News. More posts by this contributor Ride-hailing, bike and scooter companies probably raised less money than you thought To get big faster, y... |
| Oct 30, 2017 | Atlas-incubated Kymera leaps out of stealth mode, joins the hunt for game-changing protein degradation drugs | Protein degradation R&D isn’t new. Jay Bradner launched C4 Therapeutics to blaze the protein degradation approach just before he took the helm at the Novartis Institute of Biomedical Research, then recently formed a... |
| Oct 17, 2017 | What Happens When You Sell Your Startup? | 223 Shares Email Facebook Twitter LinkedIn Entrepreneurship is not just about starting businesses. Getting out on the other side, ideally richer than before, is just as important. Unless you’re one of the lucky few who start and take a comp... |
| Oct 17, 2017 | What Happens When You Sell Your Startup? | 250 Shares Email Facebook Twitter LinkedIn Entrepreneurship is not just about starting businesses. Getting out on the other side, ideally richer than before, is just as important. Unless you’re one of the lucky few who start and take a comp... |
| Jan 26, 2017 | Celgene scoops up freshman autoimmune startup Delinia in $775M buyout | Four months ago, Atlas Venture partner Saurabh Saha set up shop at the newborn Delinia with a preclinical autoimmune drug, $35 million in startup cash and a skeleton crew. Today, Celgene says it struck a deal to buy the start... |
| Sep 26, 2016 | One upside to the drug price pressure debate: more biopharma deals | A downdraft in large cap biopharma revenues, followed by generalist investor malaise about the industry as a whole, would certainly drive away some of the capital in the space. Indeed, we’ve already seen the macro impact of negative pricing... |
| Aug 22, 2016 | ‘Biocurious’ about biotech? Here are 10 must-follow Twitter accounts | Gaze into the abyss of biotech Twitter and you’ll find a bramble of obtuse acronyms, confusing abbreviations, and a weird propensity for using dollar signs as hashtags. But within that sprawl are some leading 140-character authors who provi... |
| Jul 15, 2016 | Standing on the shoulders of stem cell gene therapists | A brief retropsective of the key inflection points in stem cell gene therapy map closely to this curve (Figure B). Stem cell gene therapy technology trigger was pulled in T cells ADA-SCID was considered the ideal target for gene therapy bec... |
| Jun 29, 2016 | What will separate the winners and the losers in the immuno-oncology R&D race? | But it does raise long term strategic and capital allocation questions for cancer R&D. This blog has raised this topic a few times in the past five years. In a 2012 post, The March of the Lemmings, the a huge amount of work on a small s... |
| Jun 10, 2016 | Women demand more clout in biotech. First step? Take charge of the money | SAN FRANCISCO — There was a lot of talk this week at the global biotech convention here about rooting out sexism and bringing more women into the industry. There were some signs of progress: No scantily clad “booth babes” to attract attende... |
| Jun 9, 2016 | CRISPR/Cas9 already is a revolution in molecular biology | As you might expect given the excitement, the last 12-24 months have seen huge upswing in popular interest in CRISPR as well as in the scientific literature (see chart below). Jennifer Doudna and Emmanuelle Charpentier’s groups published th... |
| May 25, 2016 | Our Experience With First-Time Biotech CEOs: Five Behaviors That Matter | Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity–both for the newly-minted chief executive and for their board of directors. A great hire can be positively catalytic to a startup; and, sadly, ... |
| May 2, 2016 | Is the music still playing in 2016 for our dancing unicorns? | Tech VC Bill Gurley of Benchmark Capital published an excellent post a couple weeks ago about the dangers (to founders, management, employees, investors, and LPs) of the unicorn financing market. Here, I’ll muse on Gurley’s mostly tech-cent... |
| Mar 21, 2016 | Inside the race to diagnose cancer from a simple blood draw | BOSTON — It’s a medical puzzle that has snagged the attention — and the money — of Bill Gates, Jeff Bezos, and venture capitalists across the nation: Is it possible to diagnose cancer from a simple blood draw? Surgical biopsies are the norm... |
| Feb 18, 2016 | The biotech IPO markets are in turmoil: Here’s a look at the carnage | The aggregate market value of the group is actually up despite these stock numbers. The group has an aggregate market capitalization today of ~$54B, and had ~$52B of value at IPO. This is biased upward by the bigger winners, as the median m... |
| Feb 3, 2016 | What’s it like running a biotech startup outside the megaclusters? | Dictionary.com defines “outlier” as: (1) something that lies outside the main body or group that it is a part of, (2) someone who stands apart from others of his or her group, as by differing behavior, beliefs, or religious practices (Synon... |
| Jan 18, 2016 | Some closing thoughts on the J.P. Morgan Healthcare Conference | Our livers rested, our business cards sheathed – one more year of the J.P. Morgan Healthcare Conference has come and gone. Given that the week was relatively quiet in terms of breaking news, the focus rested more solidly on trend analysis, ... |
| Jan 15, 2016 | Morning Read: JP Morgan 2016 (the final chapter) | Celgene CEO: Any company that expects to have a major position in the industry a decade from now will almost have to play a big role in developing therapies for neurodegeneration. – FierceBiotech Optimism After A Stormy Week For The Biotech... |
| Jan 11, 2016 | Partners HealthCare expands life sciences innovation fund to $100M | Markell said that Partners Innovation Fund monetized three companies this year: Immuno-oncology startup CoStim Pharmaceuticals, acquired by Novartis; Adheron Therapeutics, acquired by Roche for $580 million; and Annovation Biopharma, acquir... |
| Jan 11, 2016 | #jpm16 Day 1 Buzz: Let’s get prepped, let’s get funny and let the deals begin | Photo: Flickr user Wally Gobetz Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent... |
| Jan 10, 2016 | Why the biotech party may never stop (a JPM Healthcare 2016 primer) | As I outline in a new paper out in the January 2016 issue of Nature Biotechnology, titled “This Time May Be Different”, there’s a strong case to be made that indeed this time is different. I know those are the four most dangerous words in t... |
| Jan 9, 2016 | The definitive guide to the J.P. Morgan Healthcare Conference | “Sentiment will be weary, but not funeralesque,” said Les Funtleyder, portfolio manager of E Squared Asset Management and author of the book “Health-Care Investing.” “Normally, sentiment is extremely bullish at JPMorgan, but once every few ... |
| Aug 25, 2015 | Смерть стартапа: «Диагностика — это не для слабонервных» — история медицинского сервиса On-Q-ity Статьи редакции | Мара Аспиналл, основатель стартапа On-Q-ity, занимавшегося диагностикой и профилактикой онкологических заболеваний, рассказала о том, почему в 2013 году проект, привлёкший более $31 млн инвестиций в двух раундах, вынужден был закрыться. Ком... |
| Aug 5, 2015 | RaNA Therapeutics CEO reflects: There’s no sugarcoating the process of raising biotech venture capital. It’s hard. | After all, once a decision to raise capital has been made in a public company, the process forward may be onerous, but it’s straightforward, with a number of prescribed steps. “The reason I want to highlight the grind that is involved in ra... |
| May 29, 2015 | Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | Otsuka Pharmaceutical Co Ltd lost a lawsuit challenging the U.S. Food and Drug Administration’s decision allowing other companies to make generic versions of the it’s antipsychotic drug, Abilify. Because the FDA typically grants years of ex... |
| Apr 17, 2015 | With new $280M fund, Atlas Venture cuts the IT and “right-sizes” to biotech | The new incarnation of Atlas just moved to 400 Technology Square in the life sciences-rich Kendall Park, also in Cambridge. Notably, Atlas just brought on a new chief financial officer- Ommer Chohan, former CFO of Summerhill Ventures in Tor... |
| Feb 10, 2015 | Report: How are venture dollars distributed among disease and clinical trial phase? | – More than half the venture investment goes to early stage drug companies – with 34 percent of the funding funneled into preclinical companies, and 20 percent to those in Phase 1 companies. “The clinical Phase 2 companies received 30 perce... |
| Jan 11, 2015 | Poltroons and pick-up lines: What’s buzzing at #JPM15 | Aw. Nerds are funny. Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through ... |
| Oct 21, 2014 | Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner | As the promise of harnessing the immune system to fight cancer grabs headlines around the industry, venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics, a Cambridge, MA, startup with a hybrid ... |
| Oct 15, 2014 | 30 Founders Share Why Their Startups Failed | If you're going to fail, do it fast…and write a post-mortem to share some of your learning experiences with fellow entrepreneurs. CB Insights compiled over 100 startups post-mortems that described why their startups failed. Most were w... |
| Oct 2, 2014 | Atlas Venture plans a biotech-only future via VC mitosis | For the past 35 years, Atlas Venture has operated as a diversified investor, splitting its efforts between technology and life sciences. Starting next year, the two sides will part, with the biotech team retaining the Atlas name and setting... |
| Jul 7, 2014 | Biotech and the World Cup: Some uncanny similarities | You really can’t fake it ’til you make it in soccer or in biotech – crying wolf with those infernal flops can hurt a team’s reputation, much as overpromising and failing on delivery can prove disastrous for a biotech. There are no short cut... |
| Jun 19, 2014 | J&J early stage collaborations span 3D printing for orthopedics, brown fat, biosensors | Brown fat as metabolic disorder treatment: Unlike normal fat cells, brown fat cells convert energy from food into heat. Brown fat has been a growing source of interest among scientists as a source of potential therapeutics for obesity and m... |
| Apr 9, 2014 | Spero Therapeutics catches Roche’s eye with a new way to target drug-resistant bacterial infections | Spero describes its approach as targeting a pathway involved in two critical bacterial processes: “Virulence: Our compounds directly disarm the pathogen, which will limit morbidity resistance development. Persistence: Many bacteria can adop... |
| Mar 6, 2014 | When should you take on venture debt? When you don’t need the money | For the right companies, it can be a minimally dilutive way to extend a company’s cash runway, Hoesley said. But the “right companies” are not those short on cash. “The right time to raise money from a bank is when you don’t need it,” Hoesl... |
| Mar 3, 2014 | Predictive analytics puts a new twist on startup investing for San Diego’s Correlation Ventures | Led by managing director David Coats, the San Diego-based firm calls itself an ideal co-investor, in that it removes some of the hassle from the tedious, time-consuming process of raising a VC round. Time, after all, is an entrepreneur’s bi... |
| Jan 30, 2014 | Biotech investor shares lessons learned from bad investment in healthcare | In retrospect, it’s not like Booth didn’t see potential risks with the investment. They just were not as magnified as they should have been, he writes. One of the biggest issues was the baggage of the company — it was the product of a merge... |
| Jan 17, 2014 | 3 biotech investment trends gleaned from JP Morgan conference | Corporate venture capital funds investing in innovation: A PriceWaterhouse Cooper’s report on healthcare investment trends pointed out that biotech is in the top five for corporate venture capital investing. Edward Yu, a principal at PriceW... |
| Jun 19, 2013 | Transitioning from Google Reader? While you’re at it, add these investor blogs to your feed | Written by Bruce Booth (@LifeSciVC), a self-proclaimed “recovering scientist turned early stage VC” at Atlas Ventures, this blog is one of the few focused specifically on private investing in life sciences. Booth writes about the good, the ... |
| May 1, 2013 | Atlas Venture targets early-stage biotech bets with new $265M fund | After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack ... |
| Apr 12, 2013 | On-Q-ity folds its tents after 3 years, $26M | Wall Street Beat | On-Q-ity, which raised a $26 million Series A round back in December 2009, quietly folded its tents last year after an unsuccessful bid to develop its technology for personalized cancer detection. Bruce Booth, a partner at Atlas Ventures, 1... |
| Apr 12, 2013 | East Coast Biotech Roundup: Bristol-Myers, Syros, On-Q-ity, Ziopharm | Share Share on Facebook Share on Twitter LinkedIn Email Reprints The Boston-area biotechnology cluster got a shot in the arm this week when a drug giant announced a major expansion. East Coast startups raised millions, or folded, or regroup... |
| Oct 17, 2012 | Analysis: Will biotech IPOs rescue VC backers? | Fresh off two successful biotech IPOs last week, industry watchers have begun to speculate on what the developments could mean for the beleaguered venture capital industry. Biotech promoters would love for public investors to swoon over the... |
| Jun 24, 2012 | Want To Revolutionize Health? Enable Physicians, Don't Replace Them | Doctor & Patient at Naankuse Lifeline Clinic (Photo credit: Wikipedia) |
| Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read) | TOP STORIES Johnson & Johnson (NYSE: JNJ) has accepted Cardinal Health‘s $2 billion offer to acquire vascular medical device producer, Cordis. Teva reached a $1.2 billion settlement with the Federal Trade Commission over claims that Cep... | |
| Partners HealthCare expands life sciences innovation fund to $100M | Partners HealthCare is expanding its Innovation Fund from $35 million to $100 million, the Massachusetts health system announced today at the J.P. Morgan Healthcare Conference. The fund, which was launched as an experiment in 2007 with fund... | |
| Biotech founders are turning to new VCs to raise their seed funding rounds. These are the top 19 investment firms you need to know for early-stage investing. | Sportsfile/Getty Images; Beckwith; KdT Ventures; Khosla Ventures; Rachel Mendelson/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. The amount of capital going into biotech seed ro... | |
| Biotech investor shares lessons learned from bad investment in healthcare | One of the things that makes successful serial entrepreneurs so inspiring is that even when they fail, they evaluate where they went wrong, begin again and learn from their mistakes. Frequently they share that knowledge with others. Anyone ... | |
| CRISPR/Cas9 already is a revolution in molecular biology | CRISPR/Cas9 genome editing has captured the attention of the popular media, scientific community and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certai... | |
| Spero Therapeutics catches Roche’s eye with a new way to target drug-resistant bacterial infections | Overcoming challenges posed by the growing number of infections that are resistant to traditional antibiotics is the goal of a startup surfacing today with a $3 million Series A and a drug development partnership with Roche. Spero Therapeut... | |
| #jpm16 Day 1 Buzz: Let’s get prepped, let’s get funny and let the deals begin | We are awash in what-JP-Morgan-Healthcare-2016-means conversations. But, more important, we have that rare animal known as biotech humor. Via Forbes: “The Etiquette FAQ” Photo: Flickr user Wally Gobetz Promoted 2022 Predictions driving pers... | |
| Report: How are venture dollars distributed among disease and clinical trial phase? | How are venture capital dollars are actually disseminated? Into early stage companies? Late? What fields get the most investment – cancer? Bruce Booth of Atlas Ventures blogged about this today on his Life Sci VC site about this topic, high... | |
| Founder-Focused Investing in Human Health and Biology | Recently, there have been a number of thoughtful blog posts on different models for funding emerging opportunities in human health and biology. Biotech Researchers Venture Into the Wild to Start Their Own Businesses by Jorge Conde The $10... | |
| With new $280M fund, Atlas Venture cuts the IT and “right-sizes” to biotech | Atlas Venture just closed its tenth fund at $280 million – marking its switch over to a biotech-only firm, the firm’s Bruce Booth blogged today. “At our core, we’re biotech therapeutics startup folks, and that’s where we’re going to focus,”... | |
| RaNA Therapeutics CEO reflects: There’s no sugarcoating the process of raising biotech venture capital. It’s hard. | There is no sugarcoating the process of raising capital as a private company. Or so says Ron Renaud, CEO of RaNA Therapeutics, in a guest blog on venture capitalist Bruce Booth’s website, LifeSciVC. His company recently raised $55 million i... | |
| Biotech and the World Cup: Some uncanny similarities | There are some distinct parallels between the World Cup and the biotech biz, or so says Bruce Booth of Atlas Venture in an entertaining but spot-on recent blog post. As we enter the frenzied final days of the international soccer tournament... | |
| One upside to the drug price pressure debate: more biopharma deals | The maelstrom around drug pricing has continued its fury over the past month, which has led to considerable volatility in the biopharma stock market. Investor fears of draconian price controls that will eliminate the return of investment fr... | |
| When should you take on venture debt? When you don’t need the money | Debt isn’t always a dirty word in the world of startups. Yesterday I heard John Hoesley from Silicon Valley Bank give a brief presentation on venture debt as a funding mechanism for startups at a capital connections event hosted by BioOhio.... | |
| Is JPM Week worth it from a press perspective? | By now, many of you must have read Bruce Booth’s incisive post on the value of JPM Week especially contrasted with the excess it’s associated with. Spoiler alert: He argues it’s not, but please dig into his musings. I felt myself nodding al... | |
| J&J early stage collaborations span 3D printing for orthopedics, brown fat, biosensors | A little over a year after it opened a Boston innovation center, Johnson & Johnson (NYSE: JNJ) unveiled a series of research and development collaborations and investments in early-stage companies that reads like a smorgasboard of cutti... | |
| Standing on the shoulders of stem cell gene therapists | This post initially ran on the blog Life Sci VC A new type of medicine was approved in Europe at the end of May that culminated from the successful convergence of two fields of science: stem cell transplantation and gene therapy. Strimvelis... | |
| Founders are turning to tech VCs to fund the riskiest stage of starting a drug company. It's testing the divide between the biotech and tech worlds. | This story is available exclusively to Insider subscribers. Become an Insider and start reading now. New biotech founders can face difficulties getting funding from traditional biotech VCs. They say that the VCs rarely hear outside pitches ... | |
| Is the music still playing in 2016 for our dancing unicorns? | Ex-Citigroup CEO Charles Prince famously said in July 2007, regarding Citi’s leveraged lending business, “As long as the music is playing, you’ve got to get up and dance. We’re still dancing.” Unfortunately, Chuck was still dancing four mon... | |
| The definitive guide to the J.P. Morgan Healthcare Conference | Ah. Another January, another J.P. Morgan Healthcare Conference — where this year’s biggest biopharma deals are just a cocktail and a handshake away. As swaths of C-suite execs descend upon San Francisco, here’s an overview of some of the id... | |
| Pfizer devotes $150 million to neuroscience in venture capital funding increase | New York-based drugmaker Pfizer is kicking $600 million in new funding into its venture capital arm, one-quarter of which will go toward early-stage neuroscience companies. The company said Wednesday that the fund would also hire new staff,... | |
| Transitioning from Google Reader? While you’re at it, add these investor blogs to your feed | The time has come for those of us loyal Google Reader users to buckle down and start migrating our RSS feeds to a different platform. (If you’re like me, you’ve been putting this off for the past three months.) But in the spirit of onward a... | |
| Breaking Bad стартапера: Периодическая таблица инвесторов-блогеров | Breaking Bad стартапера: Периодическая таблица инвесторов-блогеров 18 Марта, 2015, 17:15 Майя Яровая 3820 1 Сегодня многие венчурные инвесторы и ангелы активно ведут блоги, интернет-страницы или социальные аккаунты. В Украине, например, акт... |
Show more
Reviews 0
FAQ about LifeSciVC
What has the press written about LifeSciVC?
Parsers VC has collected 109 articles mentioning LifeSciVC, among them “Johnson & Johnson bets heavy on AI-driven drug discovery” (Dec 1, 2023) and “Drug developers navigating ‘biology’s century’ need a model. We made one” (Mar 15, 2023).
Is LifeSciVC still active?
Yes, LifeSciVC is active; its latest activity on Parsers VC dates from Nov 3, 2026.